|
|
||||||||


1 Department of Medical Microbiology and Genitourinary Medicine, University of Liverpool, Liverpool, UK
2 Departments of Applied Diagnostics and Computational Chemistry, GlaxoSmithKline, Medicines Research Centre, Stevenage, UK
3 Department of Virology, Hannover Medical School, Hannover, Germany
Correspondence
A. Viejo-Borbolla
aviejo{at}cnb.uam.es
Many research groups have developed targeted vectors for gene therapy based on Moloney murine leukemia virus (MoMLV). Despite proper binding of the targeted vector to the target molecule, little or no infectivity of human cells expressing the target molecule has been achieved in most studies. One of the reasons for this lack of infectivity may be steric hindrance within the targeted envelope glycoprotein (Env), impeding the conformational changes required for fusion and infection. Here, attempts were made to solve this problem by mutating key residues within Env of two targeted MoMLV-based vectors, MoMLVE-Sel and MoMLVFBP. Selection of key residues was based on an Env with reduced threshold for fusion, that of the CD4-independent human immunodeficiency virus type 2 isolate ROD/B. It was shown here that vectors bearing MoMLVFBP Env with a V512M substitution had higher titres and faster kinetics of entry than vectors bearing parental targeted Env proteins. This could be due to the partial release of steric constraints that result in an Env with a reduced threshold for fusion.
Present address: Dept of Molecular and Cell Biology, Centro Nacional de Biotecnología, CSIC; C/Darwin 3, 28049 Madrid, Spain.
Present address: Integrated Medicines Ltd, Caxton, Cambridge CB3 8PQ, UK.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |